AnPac Bio-Medical Science Co., Ltd. (ANPC): Price and Financial Metrics


AnPac Bio-Medical Science Co., Ltd. (ANPC): $0.28

-0.01 (-3.33%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ANPC to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

ANPC Stock Price Chart Interactive Chart >

Price chart for ANPC

ANPC Price/Volume Stats

Current price $0.28 52-week high $4.52
Prev. close $0.29 52-week low $0.20
Day low $0.27 Volume 301,249
Day high $0.29 Avg. volume 1,030,109
50-day MA $0.30 Dividend yield N/A
200-day MA $1.18 Market Cap 5.39M

AnPac Bio-Medical Science Co., Ltd. (ANPC) Company Bio


Anpac Bio-Medical Science Co., Ltd., a development-stage biotechnology company, researches, develops, markets, and sells multi-cancer screening and detection tests to corporations and life insurance companies in the People's Republic of China and the United States. It also manufactures cancer differentiation analysis devices; and offers physical checkup package services. The company was founded in 2010 and is headquartered in Lishui, the People's Republic of China.


ANPC Latest News Stream


Event/Time News Detail
Loading, please wait...

ANPC Latest Social Stream


Loading social stream, please wait...

View Full ANPC Social Stream

Latest ANPC News From Around the Web

Below are the latest news stories about AnPac Bio-Medical Science Co Ltd that investors may wish to consider to help them evaluate ANPC as an investment opportunity.

AnPac Bio Files CDA Device for Breakthrough Medical Device Designation Request with the FDA

PHILADELPHIA, Feb. 03, 2022 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (ANPC), a biotechnology company with operations in the United States and China focused on early cancer screening and detection, announced today that it has filed for a Breakthrough device designation request for its cancer differentiation analysis (CDA) technology based medical device with the Food and Drug Administration (FDA) on February 1, 2022. AnPac Bio’s novel CDA techno

Yahoo | February 3, 2022

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

Welcome back, trader!

William White on InvestorPlace | January 31, 2022

Leading US Market Analysis and Research Firm Ranked AnPac Bio Globally Number One in Multi-Cancer Screening and Detection Test Volume

PHILADELPHIA, Jan. 25, 2022 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (ANPC), a biotechnology company with operations in the United States and China focused on early cancer screening and detection, announced today that Frost & Sullivan Company (“Sullivan”), a leading and well-known US market analysis and research firm has ranked AnPac Bio globally as number one in worldwide multiple cancer screening and detection volume in a recent research repo

Yahoo | January 25, 2022

AnPac Bio receives Nasdaq notification regarding minimum market value (NASDAQ:ANPC)

AnPac Bio-Medical Science (ANPC) has received a written notification from the Nasdaq that the Co

Seeking Alpha | January 24, 2022

G Medical, Reviva top healthcare gainers; OPKO Health, AnPac Bio-Medical among losers

G Medical Innovations (GMVD) +18%. Reviva Pharmaceuticals (RVPH) +14%. OPKO Health (OPK) -20%. AnPac Bio-Medical Science (ANPC) -18%.

Seeking Alpha | January 24, 2022

Read More 'ANPC' Stories Here

ANPC Price Returns

1-mo 0.54%
3-mo -36.36%
6-mo -77.05%
1-year -93.33%
3-year N/A
5-year N/A
YTD -77.05%
2021 -76.98%
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.4849 seconds.